Actoplus Met and Balversa

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with erdafitinib may increase the plasma concentrations of drugs that are substrates of organic cation transporter 2 (OCT2), resulting in increased toxicity of these drugs. In vitro, erdafitinib has been shown to be an inhibitor of OCT2. However, no pharmacokinetic data are available from drug interaction studies. MANAGEMENT: Concomitant use of erdafitinib and OCT2 substrates should generally be avoided or the dose of the OCT2 substrates should be reduced based on tolerability. References "Product Information. Balversa (erdafitinib)." Janssen Products, LP, Horsham, PA.

GENERALLY AVOID: Coadministration with erdafitinib may increase the plasma concentrations of drugs that are substrates of organic cation transporter 2 (OCT2), resulting in increased toxicity of these drugs. In vitro, erdafitinib has been shown to be an inhibitor of OCT2. However, no pharmacokinetic data are available from drug interaction studies.

MANAGEMENT: Concomitant use of erdafitinib and OCT2 substrates should generally be avoided or the dose of the OCT2 substrates should be reduced based on tolerability.

Actoplus Met

Generic Name: metformin / pioglitazone

Brand name: Actoplus Met, Actoplus Met XR

Synonyms: n.a.

What is Actoplus Met?

Balversa

Generic Name: erdafitinib

Brand name: Balversa

Synonyms: n.a.

What is Balversa?